STELARA® for Adolescents with Moderate or Severe Plaque Psoriasis

Help Your Child Get Clearer Skin

The symptoms of plaque psoriasis can be tough to handle for anyone, but especially for children.
But maybe STELARA® can help.

Results You Can See

In a clinical study, most children 12 years or older with plaque psoriasis had clearer skin at
week 12, after just 2 doses of STELARA®. Talk with your child’s dermatologist to decide if
STELARA® may be the right treatment.

efficacy infographic

STELARA® isn't right for everyone. Individual results may vary.

STELARA®: A History of Plaque Psoriasis Treatment

8+ YEARS ON THE MARKET

155k PATIENTS PRESCRIBED IN THE US

Fewer Doses Per Year

Help your child stay on treatment. STELARA® is given just 4 times a year, after 2 starter doses at weeks 0 and 4. STELARA® is given as an injection under the skin. For children 12 years and older, it is recommended that STELARA® be given by a healthcare provider.

First 52 weeks of treatment

Once every 12 weeks (after 2 starter doses at weeks 0 and 4)

STELARA® is a prescription medicine used to treat adults and children 12 years and older with moderate or severe plaque psoriasis who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills).

Blocks IL-12 and IL-23 proteins involved in inflammatory immune responses

Once every week (after twice-weekly doses 
for the first three months)

ENBREL® is indicated for the treatment of patients 4 years of age or older with chronic moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Blocks TNF-alpha & beta proteins involved in inflammatory and immune responses

While frequency of treatment matters, there are other important factors to consider. Ask a dermatologist if STELARA® is right for your child.

Download our brochure to learn more about STELARA® for adolescents 12 years and older with moderate or severe plaque psoriasis.

DOWNLOAD BROCHURE

*Approved for the treatment of adult patients with moderate or severe plaque psoriasis in September 2009.

†More than 155,000 patients were prescribed STELARA® in the United States from September 2009 to August 2016. Estimations are based on calculations using product utilization data collected in the United States for STELARA® to determine patient type, average dose per administration, total number of administrations, and patient persistency rates.

‡Enbrel® is indicated for the treatment of patients 4 years or older with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy.

§Indicated trademarks are registered trademarks of their respective owners.

Get a Teen Welcome Kit

In the United States, more than 700,000 youth are diagnosed with psoriatic disease. Request a National Psoriasis Foundation (NPF) Our Spot Welcome Kit for support and resources including:

  • Interactive education booklets
  • Symptom tracker guide
  • Free 1-year subscription to Psoriasis Advance magazine
  • NPF friendship bracelet
  • Recipe to try at home, and more!

ORDER YOUR WELCOME KIT NOW